国药现代(600420.SH)：布美他尼注射液获得药品注册证书

Core Viewpoint - The company, China National Pharmaceutical Group Modern (国药现代), announced that its wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd. (国药容生), has received the drug registration certificate for Bumetanide Injection from the National Medical Products Administration [1] Group 1 - Bumetanide Injection is primarily indicated for treating edema-related diseases, including congestive heart failure, liver cirrhosis, and kidney diseases, and is used in combination with other medications for acute pulmonary edema and acute cerebral edema [1] - The drug is also indicated for hypertension, prevention of acute renal failure, hyperkalemia, hypercalcemia, dilutional hyponatremia, syndrome of inappropriate antidiuretic hormone secretion, and acute drug or toxin poisoning [1]